PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1887154
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1887154
Therapeutic Albumin Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
Growth Factors of therapeutic albumin Market
The global therapeutic albumin market is experiencing steady and sustained expansion, supported by rising incidences of critical medical conditions and increased demand in emergency care. According to the latest industry assessment, the global market was valued at USD 4.42 billion in 2024, is projected to grow to USD 4.71 billion in 2025, and reach USD 7.55 billion by 2032. The Asia Pacific region dominated the market landscape in 2024, capturing 54.52% of global revenue due to high disease prevalence and expanding plasma-based product utilization.
Therapeutic albumin is derived from human plasma and used to treat conditions such as hypovolemia, burns, hypoalbuminemia, acute liver failure, shock, and surgical complications. Its primary functions include maintaining oncotic pressure and transporting essential molecules, making it crucial for managing fluid imbalance and supporting patient recovery in severe illnesses. With chronic diseases rising globally, healthcare systems continue to expand their use of albumin-based therapies, driving consistent market growth.
Market Snapshot
- 2024 Market Size: USD 4.42 billion
- 2025 Market Size: USD 4.71 billion
- 2032 Market Size: USD 7.55 billion
- Dominant Region (2024): Asia Pacific - 54.52%
- Key Indication: Burn treatment remains dominant due to high global burn incidence.
Market Drivers
Increasing chronic disease burden is one of the most influential forces behind the market's expansion. Millions of patients globally suffer from kidney disease, liver failure, and conditions leading to hypoalbuminemia, driving hospitals to rely on albumin therapy. In April 2024, the CDC reported 6.0 million kidney disease cases and 4.5 million chronic liver disease cases in the U.S., strengthening demand for albumin in acute and critical care.
Burn injuries continue to significantly impact medical demand for albumin. As per the American Burn Association, 32,540 severe burn cases required inpatient hospitalization in 2023, including thousands with trauma-related complications. Albumin, which aids fluid balance restoration, is indispensable in such cases, contributing to the growth of the burn indication segment.
Market Restraints
The market faces supply chain and production challenges due to dependence on human-derived plasma. Shortages in voluntary blood donation hinder consistent albumin availability. In January 2024, the American Red Cross announced a 40% decline in blood donations, tightening plasma supply for albumin extraction. Such fluctuations limit manufacturers' ability to meet rising demand and contribute to price increases and global supply constraints.
Market Opportunities
Recombinant albumin technology is creating new opportunities for future growth. The rising adoption of albumin in regenerative medicine, tissue engineering, and cell therapy is broadening its clinical utility. In March 2023, Albumedix partnered with Heartseed to integrate recombinant human albumin (Recombumin) into cardiac regenerative therapy, demonstrating expanding applications beyond traditional critical care.
Advancements in plant-derived albumin, such as rice-based HSA developed by Healthgen Biotechnology in 2025, offer solutions to supply shortages and contamination risks. These innovations enhance scalability and support long-term market stability.
Market Trends
Increasing clinical trials to develop recombinant albumin products are shaping industry trends. Companies are addressing supply limitations of donor-derived albumin through biotechnology-led production. In August 2024, Shilpa Medicare completed Phase 1 trials of sRbumin, a recombinant yeast-derived albumin, highlighting rapid progress toward next-generation therapeutic albumin products. Such advancements enhance consistency, safety, and global availability.
Segmentation Overview
By Source
The human-derived albumin segment dominated in 2024 due to widespread adoption in hospitals and broad clinical applicability. Continuous approvals-such as Grifols' ALBUTEIN FlexBag-strengthen segment leadership.
By Indication
The burn segment remains dominant, supported by 6.6 million thermal burn cases annually worldwide as tracked by WHO. Rising burn incidence in India, reaching 6-7 million cases per year, contributes significantly to regional demand.
By Distribution Channel
Hospital pharmacies lead due to the intensive, hospital-based nature of albumin treatments. Albumin usage in thoracic surgeries, adopted by nearly 170 U.S. hospitals, reinforces this dominance.
Regional Outlook
Asia Pacific
Valued at USD 2.41 billion in 2024, Asia Pacific leads the global market due to high chronic disease prevalence, increasing burn injuries, and the presence of major manufacturers. China's NIFDC approval for new human albumin products is strengthening regional supply.
North America
Growth is driven by rising plasma collection capabilities and advanced production facilities. Strategic acquisitions-such as Grifols' purchase of Prometic Plasma Resources-support supply expansion.
Europe
Europe holds the second-largest share, driven by strong R&D efforts. Grifols' PRECIOSA Phase 3 trial in 2024 demonstrated survival benefits of Albutein, boosting clinical adoption.
Latin America & Middle East/Africa
Growth is supported by rising chronic disease rates, expanding plasma collection networks, and regulatory advancements for plasma therapeutics.
Conclusion
The therapeutic albumin market is poised for solid expansion-growing from USD 4.42 billion in 2024 to USD 4.71 billion in 2025, and ultimately reaching USD 7.55 billion by 2032. Rising chronic diseases, burn incidences, biotechnology innovations, and expanding regenerative medicine applications will drive the market's future trajectory.
Segmentation By Source
- Human
- Others
By Indication
- Hypovolemia
- Hypoalbuminemia
- Burn
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region
- North America (By Source, Indication, Distribution Channel, and Country)
- U.S.
- Canada
- Europe (By Source, Indication, Distribution Channel, and Country/Sub-region)
- U.K.
- Germany
- France
- Italy
- Spain
- Scandinavia
- Rest of Europe
- Asia Pacific (By Source, Indication, Distribution Channel, and Country/Sub-region)
- Japan
- China
- India
- Australia
- Southeast Asia
- Rest of Asia Pacific
- Latin America (By Source, Indication, Distribution Channel, and Country/Sub-region)
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa (By Source, Indication, Distribution Channel, and Country/Sub-region)
- GCC
- South Africa
- Rest of the Middle East & Africa
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
4. Key Insights
- 4.1. Prevalence of Key Disorders: by Key Countries/Sub-regions, 2024
- 4.2. Overview: rHSA Product Parameters
- 4.3. New Product Launches, By Key Players
- 4.4. Pipeline Analysis, By Key Players
- 4.5. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
- 4.6. Impact of COVID-19 on the Global Therapeutic Albumin Market
5. Global Therapeutic Albumin Market Analysis, Insights and Forecast, 2019-2032
- 5.1. Market Analysis, Insights and Forecast - By Source
- 5.1.1. Human
- 5.1.2. Others
- 5.2. Market Analysis, Insights and Forecast - By Indication
- 5.2.1. Hypovolemia
- 5.2.2. Hypoalbuminemia
- 5.2.3. Burn
- 5.2.4. Others
- 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
- 5.3.1. Hospital Pharmacies
- 5.3.2. Retail Pharmacies
- 5.3.3. Online Pharmacies
- 5.4. Market Analysis, Insights and Forecast - Region
- 5.4.1. North America
- 5.4.2. Europe
- 5.4.3. Asia Pacific
- 5.4.4. Latin America
- 5.4.5. Middle East & Africa
6. North America Therapeutic Albumin Market Analysis, Insights and Forecast, 2019-2032
- 6.1. Market Analysis, Insights and Forecast - By Source
- 6.1.1. Human
- 6.1.2. Others
- 6.2. Market Analysis, Insights and Forecast - By Indication
- 6.2.1. Hypovolemia
- 6.2.2. Hypoalbuminemia
- 6.2.3. Burn
- 6.2.4. Others
- 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
- 6.3.1. Hospital Pharmacies
- 6.3.2. Retail Pharmacies
- 6.3.3. Online Pharmacies
- 6.4. Market Analysis, Insights and Forecast - By Country
- 6.4.1. U.S.
- 6.4.2. Canada
7. Europe Therapeutic Albumin Market Analysis, Insights and Forecast, 2019-2032
- 7.1. Market Analysis, Insights and Forecast - By Source
- 7.1.1. Human
- 7.1.2. Others
- 7.2. Market Analysis, Insights and Forecast - By Indication
- 7.2.1. Hypovolemia
- 7.2.2. Hypoalbuminemia
- 7.2.3. Burn
- 7.2.4. Others
- 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
- 7.3.1. Hospital Pharmacies
- 7.3.2. Retail Pharmacies
- 7.3.3. Online Pharmacies
- 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 7.4.1. Germany
- 7.4.2. U.K.
- 7.4.3. France
- 7.4.4. Italy
- 7.4.5. Spain
- 7.4.6. Scandinavia
- 7.4.7. Rest of Europe
8. Asia Pacific Therapeutic Albumin Market Analysis, Insights and Forecast, 2019-2032
- 8.1. Market Analysis, Insights and Forecast - By Source
- 8.1.1. Human
- 8.1.2. Others
- 8.2. Market Analysis, Insights and Forecast - By Indication
- 8.2.1. Hypovolemia
- 8.2.2. Hypoalbuminemia
- 8.2.3. Burn
- 8.2.4. Others
- 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
- 8.3.1. Hospital Pharmacies
- 8.3.2. Retail Pharmacies
- 8.3.3. Online Pharmacies
- 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 8.4.1. China
- 8.4.2. Japan
- 8.4.3. India
- 8.4.4. Australia
- 8.4.5. Southeast Asia
- 8.4.6. Rest of Asia Pacific
9. Latin America Therapeutic Albumin Market Analysis, Insights and Forecast, 2019-2032
- 9.1. Market Analysis, Insights and Forecast - By Source
- 9.1.1. Human
- 9.1.2. Others
- 9.2. Market Analysis, Insights and Forecast - By Indication
- 9.2.1. Hypovolemia
- 9.2.2. Hypoalbuminemia
- 9.2.3. Burn
- 9.2.4. Others
- 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
- 9.3.1. Hospital Pharmacies
- 9.3.2. Retail Pharmacies
- 9.3.3. Online Pharmacies
- 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 9.4.1. Brazil
- 9.4.2. Mexico
- 9.4.3. Rest of Latin America
10. Middle East & Africa Therapeutic Albumin Market Analysis, Insights and Forecast, 2019-2032
- 10.1. Market Analysis, Insights and Forecast - By Source
- 10.1.1. Human
- 10.1.2. Others
- 10.2. Market Analysis, Insights and Forecast - By Indication
- 10.2.1. Hypovolemia
- 10.2.2. Hypoalbuminemia
- 10.2.3. Burn
- 10.2.4. Others
- 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
- 10.3.1. Hospital Pharmacies
- 10.3.2. Retail Pharmacies
- 10.3.3. Online Pharmacies
- 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 10.4.1. GCC
- 10.4.2. South Africa
- 10.4.3. Rest of Middle East & Africa
11. Competitive Analysis
- 11.1. Global Market Share Analysis (2024)
- 11.2. Company Profiles
- 11.2.1. Takeda Pharmaceutical Company Limited.
- 11.2.1.1. Overview
- 11.2.1.2. Products
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Strategies
- 11.2.1.6. Financials (Based on Availability)
- 11.2.2. CSL
- 11.2.2.1. Overview
- 11.2.2.2. Products
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Strategies
- 11.2.2.6. Financials (Based on Availability)
- 11.2.3. Grifols, S.A.
- 11.2.3.1. Overview
- 11.2.3.2. Products
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Strategies
- 11.2.3.6. Financials (Based on Availability)
- 11.2.4. Octapharma AG
- 11.2.4.1. Overview
- 11.2.4.2. Products
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Strategies
- 11.2.4.6. Financials (Based on Availability)
- 11.2.5. Kedrion S.p.A.
- 11.2.5.1. Overview
- 11.2.5.2. Products
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Strategies
- 11.2.5.6. Financials (Based on Availability)
- 11.2.6. Biotest AG
- 11.2.6.1. Overview
- 11.2.6.2. Products
- 11.2.6.3. SWOT Analysis
- 11.2.6.4. Recent Developments
- 11.2.6.5. Strategies
- 11.2.6.6. Financials (Based on Availability)
- 11.2.7. LFB (France)
- 11.2.7.1. Overview
- 11.2.7.2. Products
- 11.2.7.3. SWOT Analysis
- 11.2.7.4. Recent Developments
- 11.2.7.5. Strategies
- 11.2.7.6. Financials (Based on Availability)
- 11.2.8. China Biologic Products Holdings, Inc.
- 11.2.8.1. Overview
- 11.2.8.2. Products
- 11.2.8.3. SWOT Analysis
- 11.2.8.4. Recent Developments
- 11.2.8.5. Strategies
- 11.2.8.6. Financials (Based on Availability)
- 11.2.9. Baxter
- 11.2.9.1. Overview
- 11.2.9.2. Products
- 11.2.9.3. SWOT Analysis
- 11.2.9.4. Recent Developments
- 11.2.9.5. Strategies
- 11.2.9.6. Financials (Based on Availability)
- 11.2.1. Takeda Pharmaceutical Company Limited.
List of Tables
- Table 1: Global Therapeutic Albumin Market Revenue (USD billion) Forecast, by Source, 2019-2032
- Table 2: Global Therapeutic Albumin Market Revenue (USD billion) Forecast, by Indication, 2019-2032
- Table 3: Global Therapeutic Albumin Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
- Table 4: Global Therapeutic Albumin Market Revenue (USD billion) Forecast, by Region, 2019-2032
- Table 5: North America Therapeutic Albumin Market Revenue (USD billion) Forecast, by Source, 2019-2032
- Table 6: North America Therapeutic Albumin Market Revenue (USD billion) Forecast, by Indication, 2019-2032
- Table 7: North America Therapeutic Albumin Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
- Table 8: North America Therapeutic Albumin Market Revenue (USD billion) Forecast, By Country, 2019-2032
- Table 9: Europe Therapeutic Albumin Market Revenue (USD billion) Forecast, by Source, 2019-2032
- Table 10: Europe Therapeutic Albumin Market Revenue (USD billion) Forecast, by Indication, 2019-2032
- Table 11: Europe Therapeutic Albumin Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
- Table 12: Europe Therapeutic Albumin Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
- Table 13: Asia Pacific Therapeutic Albumin Market Revenue (USD billion) Forecast, by Source, 2019-2032
- Table 14: Asia Pacific Therapeutic Albumin Market Revenue (USD billion) Forecast, by Indication, 2019-2032
- Table 15: Asia Pacific Therapeutic Albumin Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
- Table 16: Asia Pacific Therapeutic Albumin Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
- Table 17: Latin America Therapeutic Albumin Market Revenue (USD billion) Forecast, by Source, 2019-2032
- Table 18: Latin America Therapeutic Albumin Market Revenue (USD billion) Forecast, by Indication, 2019-2032
- Table 19: Latin America Therapeutic Albumin Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
- Table 20: Latin America Therapeutic Albumin Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
- Table 21: Middle East & Africa Therapeutic Albumin Market Revenue (USD billion) Forecast, by Source, 2019-2032
- Table 22: Middle East & Africa Therapeutic Albumin Market Revenue (USD billion) Forecast, by Indication, 2019-2032
- Table 23: Middle East & Africa Therapeutic Albumin Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
- Table 24: Middle East & Africa Therapeutic Albumin Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
List of Figures
- Figure 1: Global Therapeutic Albumin Market Revenue Breakdown (USD billion, %) by Region, 2024 & 2032
- Figure 2: Global Therapeutic Albumin Market Value Share (%), by Source, 2024 & 2032
- Figure 3: Global Therapeutic Albumin Market Value Share (%), by Indication, 2024 & 2032
- Figure 4: Global Therapeutic Albumin Market Value Share (%), by Distribution Channel, 2024 & 2032
- Figure 5: Global Therapeutic Albumin Market Value Share (%), by Region, 2024 & 2032
- Figure 6: North America Therapeutic Albumin Market Value (USD billion), by Source, 2024 & 2032
- Figure 7: North America Therapeutic Albumin Market Value Share (%), by Source, 2024
- Figure 8: North America Therapeutic Albumin Market Value (USD billion), by Indication, 2024 & 2032
- Figure 9: North America Therapeutic Albumin Market Value Share (%), by Indication, 2024
- Figure 10: North America Therapeutic Albumin Market Value (USD billion), by Distribution Channel, 2024 & 2032
- Figure 11: North America Therapeutic Albumin Market Value Share (%), by Distribution Channel, 2024
- Figure 12: North America Therapeutic Albumin Market Value (USD billion), By Country, 2024 & 2032
- Figure 13: North America Therapeutic Albumin Market Value Share (%), By Country, 2024
- Figure 14: Europe Therapeutic Albumin Market Value (USD billion), by Source, 2024 & 2032
- Figure 15: Europe Therapeutic Albumin Market Value Share (%), by Source, 2024
- Figure 16: Europe Therapeutic Albumin Market Value (USD billion), by Indication, 2024 & 2032
- Figure 17: Europe Therapeutic Albumin Market Value Share (%), by Indication, 2024
- Figure 18: Europe Therapeutic Albumin Market Value (USD billion), by Distribution Channel, 2024 & 2032
- Figure 19: Europe Therapeutic Albumin Market Value Share (%), by Distribution Channel, 2024
- Figure 20: Europe Therapeutic Albumin Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
- Figure 21: Europe Therapeutic Albumin Market Value Share (%), By Country/ Sub-region, 2024
- Figure 22: Asia Pacific Therapeutic Albumin Market Value (USD billion), by Source, 2024 & 2032
- Figure 23: Asia Pacific Therapeutic Albumin Market Value Share (%), by Source, 2024
- Figure 24: Asia Pacific Therapeutic Albumin Market Value (USD billion), by Indication, 2024 & 2032
- Figure 25: Asia Pacific Therapeutic Albumin Market Value Share (%), by Indication, 2024
- Figure 26: Asia Pacific Therapeutic Albumin Market Value (USD billion), by Distribution Channel, 2024 & 2032
- Figure 27: Asia Pacific Therapeutic Albumin Market Value Share (%), by Distribution Channel, 2024
- Figure 28: Asia Pacific Therapeutic Albumin Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
- Figure 29: Asia Pacific Therapeutic Albumin Market Value Share (%), By Country/ Sub-region, 2024
- Figure 30: Latin America Therapeutic Albumin Market Value (USD billion), by Source, 2024 & 2032
- Figure 31: Latin America Therapeutic Albumin Market Value Share (%), by Source, 2024
- Figure 32: Latin America Therapeutic Albumin Market Value (USD billion), by Indication, 2024 & 2032
- Figure 33: Latin America Therapeutic Albumin Market Value Share (%), by Indication, 2024
- Figure 34: Latin America Therapeutic Albumin Market Value (USD billion), by Distribution Channel, 2024 & 2032
- Figure 35: Latin America Therapeutic Albumin Market Value Share (%), by Distribution Channel, 2024
- Figure 36: Latin America Therapeutic Albumin Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
- Figure 37: Latin America Therapeutic Albumin Market Value Share (%), By Country/ Sub-region, 2024
- Figure 38: Middle East & Africa Therapeutic Albumin Market Value (USD billion), by Source, 2024 & 2032
- Figure 39: Middle East & Africa Therapeutic Albumin Market Value Share (%), by Source, 2024
- Figure 40: Middle East & Africa Therapeutic Albumin Market Value (USD billion), by Indication, 2024 & 2032
- Figure 41: Middle East & Africa Therapeutic Albumin Market Value Share (%), by Indication, 2024
- Figure 42: Middle East & Africa Therapeutic Albumin Market Value (USD billion), by Distribution Channel, 2024 & 2032
- Figure 43: Middle East & Africa Therapeutic Albumin Market Value Share (%), by Distribution Channel, 2024
- Figure 44: Middle East & Africa Therapeutic Albumin Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
- Figure 45: Middle East & Africa Therapeutic Albumin Market Value Share (%), By Country/ Sub-region, 2024
- Figure 46: Global Therapeutic Albumin Market Share (%), By Company, 2024
